Chargement en cours...
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
During recent years, the therapeutic landscape in chronic myeloid leukemia (CML) has changed significantly. Since the clinical introduction of tyrosine kinase inhibitors (TKIs) approximately 15 years ago, patients’ concerns have shifted from reduced life expectancy toward long-term toxicities of TKI...
Enregistré dans:
| Publié dans: | J Blood Med |
|---|---|
| Auteurs principaux: | , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Dove Medical Press
2018
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905837/ https://ncbi.nlm.nih.gov/pubmed/29695943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S129821 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|